###### Strengths and limitations of this study

-   The use of an individual patient data meta-analysis of randomised controlled trials (RCTs) will provide more precise estimates of the placebo response. It also allows the identification of patient-level predictors of placebo response in this population.

-   The study will be conducted within the framework of the OA Trial Bank, an international organisation that initiates meta-analyses of effect on predefined subgroups of OA patients from existing trials.

-   Identification of the predictors of placebo response in intra-articular injections for OA may influence future clinical trial designs with a more tailored approach when classifying participants in future studies.

-   Inclusion of frequently utilised intra-articular injection RCTs will allow for a larger sample size, increased precision of the results and provide insight into the more commonly used injectables.

-   We have only included injections of corticosteroid and viscosupplements/hyaluronic acid trials because these are the standard intra-articular treatments for OA. There are other intra-articular injection treatments such as blood products, growth factors and prolotherapy. As they are not established treatments with limited evidence in OA, we will exclude them from this study.

Introduction {#s1}
============

Osteoarthritis (OA) is a highly prevalent condition that imposes a substantial burden on the individuals affected. It is estimated that by 2030, 25% of the population of the USA (67 million adults) will have OA.[@R1] Current management strategies suggest a focus towards conservative therapies including physiotherapy and weight loss, as well as pain palliation whether it is in the form of medications or ultimately joint replacement surgery.[@R2] However, for patients, especially with only symptomatic monoarthritis or oligoarthritis, the systematic effects of oral medications raises safety concerns.[@R3] Intra-articular injection therapies appear to be an attractive alternative in these patients, and there is a trend in the development of investigational intra-articular agents, aiming to improve symptoms and potentially alter disease progression.

Presently available intra-articular therapies are corticosteroids and viscosupplements (hyaluronic acid).[@R7] Agents such as blood-derived products are also available in some countries. However, based on current guidelines for knee OA, intra-articular injections are not first-line therapies and are preferred as the last non-operative alternative where other conservative modalities have failed, or in some published treatment guidelines, not recommended at all based on their limited evidence, or controversial efficacy profiles.[@R9]

There are a number of methodological limitations of clinical trials in OA that have constrained progress. Especially with intra-articular therapies in OA, most trials are small, thus affecting the strength of the studies. Another issue is the frequent practice of comparing one controversial agent versus another (ie, platelet-rich plasma versus hyaluronate agent), which will not justify the agent to be superior in the overall treatment of OA. Furthermore, in intra-articular therapy trials, there are concerns of whether intra-articular injection of normal saline should be considered as the ideal agent to be employed as a placebo. There are increasing number of studies contributing to the evidence of intra-articular saline having a potential biological effect. The biological effect in this setting is likely secondary to neurobiological mechanisms such as those via endogenous opioid and dopaine,[@R11] as well as via possible dilution of the inflammatory element in the joint because of the volume of saline.[@R12] Thus, intra-articular saline as a placebo can be considered to be an 'impure placebo' in the context of a placebo-controlled intra-articular injection trial. The inclusion of a no-treatment/sham-injection group may be a way to discern the placebo effect of saline injections, however the presence of this design is rare in OA clinical trials. Despite this, previous meta-analysis of randomised controlled trials (RCTs) assessing the placebo response across a range of therapies in OA (non-pharmacological, pharmacological and surgical treatments) have confirmed that placebo response (effect size (ES)=0.51 95% CI 0.46 to 0.55) is greater than no treatment or spontaneous response (ES=0.03, 95% CI −0.13 to 0.18) for pain in OA.[@R14]

The inability to demonstrate a minimum clinically important difference (MCID) over placebo, directly affects the development of potential pharmacological innovations and their translation to becoming commercially available treatment options for this disabling disease. The magnitude of the placebo response in OA trials is significant with about 75% of treatment effect being attributable to placebo contextual effects.[@R15] In general, the more invasive and more frequent the administration of an intervention, the larger the placebo response. For invasive therapies, patients' expectations and beliefs create even larger placebo/contextual effects.[@R14] When considering clinical trial design, the challenges of which placebo to choose, its volume, injection frequency, the use of injection guidance, concomitant local anaesthetic use, patient baseline disease presentation (bilateral vs unilateral disease, concomitant presence of inflammatory features/effusion, disease severity, baseline pain) all create substantial opportunity for heterogeneity in what is already a challenging clinical trial environment. The intervention itself is also subject to contextual effects; administration route, colour, branding and cost all have an effect, thus indicating that clinical trials may need more standardisation across the board to optimise the demonstration of treatment response.[@R16]

To date, placebo responses from clinical trials are ultimately measured as a change in outcome from baseline in the placebo group in comparison to the treatment group and is potentially confounded by spontaneous effects such as the Hawthorne effect (ie, the effect due to being observed), natural fluctuation of disease and regression to the mean.[@R14] Minimal trials incorporate a no-treatment group, which may allow for adequate clarification of the placebo effect. Meta-analysis of OA treatments has shown that the placebo response varies greatly between individuals.[@R15] The main limitation of aggregate data meta-analysis is that the variations of the treatment/placebo responses across individuals cannot be scrutinised. As the placebo response can be attributed to the individual or related to the study protocol, assessment of the placebo response utilising individual patient data (IPD) meta-analysis will give insight into the different predictors of placebo response. IPD analysis is now increasingly used over established meta-analysis and is considered to be superior, as it facilitates standardisation of analyses across different studies and allow derivation of the desired information.[@R17] Our IPD meta-analysis will examine the role of potential placebo response modifiers, assessing patient, intervention and trial characteristics---contextual factors that are rarely measured and reported in clinical trials or analysed in existing meta-analyses.

This analysis will be conducted under the auspices of the OA Trial Bank, an international collaboration that is endorsed by the Osteoarthritis Research Society International and the European League Against Rheumatism (EULAR). The OA Trial Bank was initiated in 2010 with the purpose of collecting and analysing IPD of published RCTs in OA to identify specific responseive subgroups for the different OA treatment. It brings together data from individuals with a diagnosis of OA, recruited for published RCTs from around the world to form a databank.[@R18]

Therefore, the aim of this IPD analysis is to investigate the predictors of placebo response in intra-articular injection trials in OA. This study will differ from the recently submitted IPD-meta-analysis protocol assessing placebo response in OA by University of Nottingham arthritis research group.[@R19] Based on their published protocol, their data extraction from the OA Trial Bank is targeted at OA therapies namely topical non-steroidal anti-inflammatory drugs, topical capsaicin, glucosamine and intra-articular glucocorticoids. Potential placebo response modifiers that will be assessed are: patient baseline characteristics (age, gender and body mass index), disease (radiographic information, signs of inflammation, muscle strength, duration of complaints, pain severity, type of pain, central sensitisation and psychological assessments), placebo (oral, topical, injection and dose) and trial and outcome measures (pain, function, patient global assessment and quality of life).[@R19] In contrast, intra-articular injection therapies will be the only therapies of interest in this analysis. While there will be some cross over regarding patient-level characteristics, the incorporation of viscosupplementation/hyaluronic acid trials and an updated systematic review with the acquisition of newer glucocorticoid trials which will allow for a larger sample size, increased precision of the results and provide insight into the more commonly used injectables. In addition to patient-level characteristics, there will be a focus on interventional and trial characteristics, that is, intervention characteristics (aspirate volume, frequency of injection, volume of injection and intra-articular injection approach) and trial characteristics (clinical setting, blinding, use of intention to treat analysis and funder/sponsor).

Methods and analysis {#s2}
====================

IPD from trials comparing intra-articular injection to placebo for knee OA will be extracted and reanalysed to ascertain the magnitude of the placebo response and the role of potential predictors in these trials. The analysis will be conducted under the umbrella of the OA Trial Bank.

The IPD meta-analysis will be conducted in accordance with the methods recommended by the IPD Meta-analysis Methods Group.[@R17] Reporting of the meta-analysis will conform with the Preferred Reporting Items for Systematic review and Meta-Analysis (PRISMA)-IPD checklist.[@R20]

The research question and study proposal of this study has been approved by the steering committee of the OA Trial Bank, before the development of the full study protocol.

Participants {#s2a}
------------

Participants from the identified RCTs must have a diagnosis of knee and hip OA, according to the criteria defined by the American College of Rheumatology, EULAR evidence-based recommendations for the diagnosis of knee OA[@R21] or fulfil specified radiological criteria of OA diagnosis.

Types of baseline assessments {#s2b}
-----------------------------

Participant baseline characteristics including age, gender, bilateral versus unilateral disease, other joint OA involvement, radiographic severity, pain severity at baseline and presence of inflammatory features (based on imaging and physical examination). Intervention characteristics (clinical setting, aspirate volume, frequency of injection, volume of injection and intra-articular injection approach) and trial design characteristics (blinding, dropout rate, use of intention to treat analysis, role of funder/sponsor) will also be extracted.

Types of outcomes {#s2c}
-----------------

The primary outcome of the IPD meta-analysis will be change in pain over time. Visual analogue scale (VAS) pain score will be preferentially used for the analysis. If unavailable, the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score will be used and converted into a VAS 0--100 scale as per previous OA Trial Bank Protocols.[@R23]

Secondary outcomes will be a change in function and patient global assessment.

Language {#s2d}
--------

No language restrictions will apply.

Literature search {#s2e}
-----------------

### Identification of studies {#s2e1}

A systematic literature search will be conducted using the following databases: Pubmed (Medline), EMBASE, Web of Science, Cochrane Central and SCOPUS. The search will be from inception to September 2018. The search strategy was developed by the reviewers in consultation with the OA Trial Bank (online [supplementary appendix 1](#SP1){ref-type="supplementary-material"}).

10.1136/bmjopen-2018-027372.supp1

Literature searches will be done separately for intra-articular glucocorticoid and viscosupplementation/hyaluronic acid. The literature search approach will comprise of an amalgamation of main search terms including identification of the OA population group, intervention of intra-articular glucocorticoid and viscosupplementation/hyaluronic acid and of RCT design. Furthermore, efforts will be made to identify unpublished trials through Clinicaltrials.gov, European Union Clinical Trials Register and International Standard Randomised Controlled Trials Number (ISRCTN) registry and contacting pharmaceutical suppliers.

Identified studies will be imported to EndNote X8 for screening.

### Screening process {#s2e2}

Studies eligible for inclusion will be assessed by two independent reviewers (SY and LD). Titles and abstracts for potential studies will be screened first, and subsequently, the full text of the selected studies will be reviewed for appropriateness to be included. If no consensus is reached, a third reviewer will be consulted (DJH). The results will be summarised as per the PRISMA guidelines.[@R24]

Type of studies {#s2f}
---------------

Randomised placebo-controlled trials of intra-articular glucocorticoids and/or viscosupplementation/hyaluronic acid in knee or hip OA will be included. Studies related to inflammatory arthritis (such as rheumatoid or psoriatic arthritis) will be excluded. Animal model and biomarker studies will be excluded. Trials that are not randomised, literature or systematic reviews, and conference abstracts without available data will be excluded.

Data collection and transfer {#s2g}
----------------------------

As per all other studies conducted by the OA Trial Bank,[@R18] the same method for data acquisition and transfer will be utilised. The corresponding authors of eligible trials will be invited to collaborate. Initial contact will be by email with two further successive email reminders. If the corresponding author is uncontactable, communication will be attempted with the other trial authors and/or institutions listed. Authors who are willing to collaborate will be asked to sign a data delivery agreement from the OA Trial Bank. This will include items of input data, ownership of data, obligation, terms, authorship and subsequent publication intentions. The data obtained will be stored on a secure server at Erasmus MC University Medical Center, Rotterdam, the Netherlands, and participant details will be kept in an anonymous and confidential fashion. Data quality will be ensured through independent checking looking at data-entry mistakes and inconsistencies. Data received will be compared with the published summary results from the primary studies. In situations where there are differences found, the authors will be contacted to resolve the discrepancy issue.

With the existing intra-articular glucocorticoid trials that have been stored in the OA Trial Bank, the corresponding authors will be contacted and will be asked to sign a further data transfer agreement for the use of their data for the purpose of this analysis.

Patient and public involvement {#s2h}
------------------------------

There have been no patient and/or public involvement in the design of this IPD meta-analysis.

Risk and quality assessment {#s2i}
---------------------------

The included trials will be assessed independently by two reviewers to assess the quality of evidence and the risk of biases through the use of the Cochrane Collaboration's tool.[@R26] A third reviewer will be consulted if there is a disagreement. The domains assessed will include randomisation of procedure, blinding of participants, physicians and treatment allocation, use of intention to treat analysis, incomplete outcome data, baseline group similarity, reporting bias and other sources of biases. Studies will be categorised as 'low risk', 'high risk' or 'unclear. As per previous studies with the OA trial bank, a low risk of bias study will be classified as fulfilling at least 6 of the 12 items in the Cochrane Collaboration's tool.[@R27]

Data analysis {#s2j}
-------------

A descriptive evaluation of each trial and study participants will be conducted. Publication bias will be investigated using a funnel plot analysis as this will specify the potential impact of both known and unknown missing trials on the results.[@R27] Missing data will be assumed to be missing at random, thus patient characteristics will be used to impute missing data by means of multiple imputation at random.[@R29] In addition, we will compare the ESs pooled from those responded versus the overall (ie, the ES pooled from all trials systematically searched from the literature) to examine the deviation.

Baseline and follow-up data from the placebo arm will be used to estimate the predictors of the placebo response. Separate analyses will be conducted for glucocorticoids and viscosupplementation/hyaluronic acid, as well as different outcome measures (ie, pain, function and patient global assessment). Trials will also be grouped by type of joint (ie, knee or hip) and follow-up duration (eg, \<4 weeks or ≥4 weeks for corticosteroid and \<12 weeks or ≥12 weeks for viscosupplementation/hyaluronic acid).

A one-step approach will be applied, via the use of multilevel regression models to assess for predictors of the placebo response. The use of the one step approach in this setting will allow for a more cohesive modelling of covariates and account for the clustering of participants within the study.[@R17] This will be done by combining all the data from all the studies available after appropriate standardisation of the variables and a new dataset will be formed to allow for further analysis. To assess for the potential subgroup effects, a random effect model will be utilised given the hierarchical nature of the data to assess the interaction effects, with change in pain being a dependent variable and potential predictors being independent variables. In the setting where a no-treatment control is available, we will include placebo-no-treatment as an independent variable. Responders to placebo will be compared with non-responders to identify predictors of response.

The primary outcome will be change in pain from baseline and will be determined as the dependent variable in the regression model. The MCID threshold will be a 20% or more reduction in pain based on the VAS pain score with 0 mm being no pain to 100 mm being the worst pain ever. This level has been recommended for use in pain and function assessment in rheumatic diseases such as OA,[@R31] and we will use it to define the placebo response which is equivalent to an ES of 0.8,[@R33] that indicates the response unlikely to be caused by spontaneous effects. In situations where WOMAC pain score is only available, it will be used instead.

Secondary outcomes will be a change in function and patient global assessment. Change in pain will be determined as the dependent variable, and independent variables will be the potential predictors of placebo response. These will be grouped as patient-level characteristics, peripheral pain mechanisms, central pain mechanisms, intervention characteristics and those related to trial design (blinding, funder/sponsor roles and intention to treat) ([table 1](#T1){ref-type="table"}) and are as listed below. Each group will be forced into multivariate models with a final model including all groups.

###### 

Potential placebo response modifiers

  Study features                                                                                            Description
  --------------------------------------------------------------------------------------------------------- -------------------------------------------------
  Patient domain                                                                                            Age
  Gender                                                                                                    
  Body mass index                                                                                           
  Bilateral versus unilateral disease                                                                       
  Disease duration                                                                                          
  Pain mechanisms                                                                                           Central pain mechanisms:
   Osteoarthritis in other joints.                                                                          
   Comorbidities.                                                                                           
   Pain severity.                                                                                           
  Peripheral pain mechanisms:                                                                               
   Radiographic information.                                                                                
   Presence of inflammatory features (ultrasound versus physician assessed joint swelling).                 
   Morning stiffness symptoms.                                                                              
  Intervention characteristics                                                                              Clinical setting (ie, location of intervention)
  Aspirate volume                                                                                           
  Frequency of injection                                                                                    
  Volume of injection                                                                                       
  Intra-articular injection approach (ie, medial vs lateral approach, use of ultrasound guided injection)   
                                                                                                            Blinding
  Dropout rates per group                                                                                   
  Inclusion of a 'no treatment' group                                                                       
  Use of 'intention to treat analysis'                                                                      
  Randomisation ratio                                                                                       
  Trial duration                                                                                            
  Single centre/multicentre study                                                                           
  Parallel/crossover trial                                                                                  
  Funding/sponsor (ie, pharmaceutical funding)                                                              

1.  Patient characteristics: age, gender, body mass index, bilateral versus unilateral disease and disease duration.

2.  Pain mechanisms: peripheral pain mechanisms (ie, signs of inflammation, morning stiffness symptoms and radiographic findings), central pain mechanisms (ie, other joint OA, comorbidities and pain severity).

3.  Intervention characteristics: clinical setting (ie, location of intervention), aspirate volume, frequency of injection, volume of injection, and intra-articular injection approach (ie, medial vs lateral approach and use of ultrasound-guided injection).

4.  Trial characteristics: blinding (patients, assessors or physicians), dropout rates, role of funder/sponsor (ie, pharmaceutical company), randomisation ratio, trial duration, single centre/multicentre study, parallel/cross-over trial and use of 'intention to treat' analysis.

The trials that originate the IPD will also be coded and included as a level variable in all analyses. ESs and 95% CI will be generated for each outcome measure. P\<0.05 will be considered statistically significant.

A sensitivity analysis will be conducted using pain scores (instead of change in pain scores) as a continuous dependent variable and repeating the approaches described above.

Statistical analyses will be performed using Stata SE V.14.

Expected research contribution {#s3}
==============================

It is envisaged that the investigators will deliver data to be used in the design and execution of future clinical trials. It will allow for better understanding of the placebo response and subsequent implementation of clinical designs with lowered placebo responses.

Ethics and dissemination {#s4}
========================

This study does not include identifiable data. Ethical approval was obtained by the original investigators. Results of the IPD meta-analysis will be disseminated for publication in a peer-reviewed journal and by international conference presentations.
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